MRI in multiple sclerosis: correlation with expanded disability status scale (EDSS)

被引:162
作者
Barkhof, F
机构
[1] Free Univ Amsterdam Hosp, MS MRI Ctr, NL-1007 MB Amsterdam, Netherlands
[2] Free Univ Amsterdam Hosp, Dept Radiol, NL-1007 MB Amsterdam, Netherlands
关键词
magnetic resonance imaging; multiple sclerosis; expanded disability status scale;
D O I
10.1177/135245859900500415
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Magnetic resonance (MR) imaging is very sensitive in showing disseminated MS lesions. Subclinical MR progression occurs frequently, explaining why MR is now used to monitor treatment even without measurable consequences, of new MR lesions to the Patient at this moment In the light of this clinico-radiological paradox, the significance of MR in MS is discussed, particularly in relation with the expanded disability status scale (EDSS). Gadolinium-enhancing lesions correlate with the occurrence of relapses, CSF myelin breakdown products end, in patients with relapsing-remitting disease with higher EDSS. However, the predictive value of the frequency of enhancement for changes in EDSS is only weak. For conventional R-weighted MR imaging the cross-sectional correlation with EDSS varies between 0.15 and 0.60 and is limited mainly by the inherent lack of tissues specificity of R-weighted images. Both TI block holes and magnetisation transfer (MT) parameters show a better correlation with EDSS; it should be noted that lesions in which those abnormalities are found go through on initial phase of enhancement as well. For TI block holes, a correlation up to 0.81 has been reported for SP patients. Post-mortem studies show that black holes and low MT ratios are in vivo markers of axonal loss. Preliminary data indicate that progressive atrophy also correlates with progression on the EDSS scale. More should be learned about the fate of new MR lesion with regards to development of axonal loss, which at present is difficult to predict in the enhancing stage. The existence of escape mechanisms, including remyelination, make a simple correlation with EDSS extremely unlikely, and perhaps not even desirable. Nevertheless, while the clinical effect of a given new lesion may be difficult to ascertain, the absence of (new) MR lesions is prognostically favourable as will be the degree to which new lesions ore prevented by treatment.
引用
收藏
页码:283 / 286
页数:4
相关论文
共 35 条
  • [1] [Anonymous], 1970, Handbook of clinical neurology
  • [2] Imaging of remyelination
    Barkhof, F
    [J]. MULTIPLE SCLEROSIS, 1997, 3 (02): : 129 - 132
  • [3] A CORRELATIVE TRIAD OF GADOLINIUM-DTPA MRI, EDSS, AND CSF-MBP IN RELAPSING MULTIPLE-SCLEROSIS PATIENTS TREATED WITH HIGH-DOSE INTRAVENOUS METHYLPREDNISOLONE
    BARKHOF, F
    FREQUIN, STFM
    HOMMES, OR
    LAMERS, K
    SCHELTENS, P
    VANGEEL, WJA
    VALK, J
    [J]. NEUROLOGY, 1992, 42 (01) : 63 - 67
  • [4] Brodsky M, 1997, NEUROLOGY, V49, P1404
  • [5] Inflammatory central nervous system demyelination: Correlation of magnetic resonance imaging findings with lesion pathology
    Bruck, W
    Bitsch, A
    Kolenda, H
    Bruck, Y
    Stiefel, M
    Lassmann, H
    [J]. ANNALS OF NEUROLOGY, 1997, 42 (05) : 783 - 793
  • [6] CORRELATIONS BETWEEN CHANGES IN DISABILITY AND T-2-WEIGHTED BRAIN MRI ACTIVITY IN MULTIPLE-SCLEROSIS - A FOLLOW-UP-STUDY
    FILIPPI, M
    PATY, DW
    KAPPOS, L
    BARKHOF, F
    COMPSTON, DAS
    THOMPSON, AJ
    ZHAO, GJ
    WILES, CM
    MCDONALD, WI
    MILLER, DH
    [J]. NEUROLOGY, 1995, 45 (02) : 255 - 260
  • [7] CORRELATION OF MAGNETIZATION-TRANSFER RATIO WITH CLINICAL DISABILITY IN MULTIPLE-SCLEROSIS
    GASS, A
    BARKER, GJ
    KIDD, D
    THORPE, JW
    MACMANUS, D
    BRENNAN, A
    TOFTS, PS
    THOMPSON, AJ
    MCDONALD, WI
    MILLER, DH
    [J]. ANNALS OF NEUROLOGY, 1994, 36 (01) : 62 - 67
  • [8] MRI lesion volume measurement in multiple sclerosis and its correlation with disability: a comparison of fast fluid attenuated inversion recovery (fFLAIR) and spin echo sequences
    Gawne-Cain, ML
    O'Riordan, JI
    Coles, A
    Newell, B
    Thompson, AJ
    Miller, DH
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1998, 64 (02) : 197 - 203
  • [9] Intramuscular interferon beta-1 alpha for disease progression in relapsing multiple sclerosis
    Jacobs, LD
    Cookfair, DL
    Rudick, RA
    Herndon, RM
    Richert, JR
    Salazar, AM
    Fischer, JS
    Goodkin, DE
    Granger, CV
    Simon, JH
    Alam, JJ
    Bartoszak, DM
    Bourdette, DN
    Braiman, J
    Brownscheidle, CM
    Coats, ME
    Cohan, SL
    Dougherty, DS
    Kinkel, RP
    Mass, MK
    Munschauer, FE
    Priore, RL
    Pullicino, PM
    Scherokman, BJ
    WeinstockGuttman, B
    Whitman, RH
    Baird, WC
    Fillmore, M
    Bona, LM
    ColonRuiz, ME
    Nadine, BS
    Donovan, A
    Bennett, S
    Kieffer, YM
    Umhauer, MA
    Miller, CE
    Kilic, AK
    Sargent, EL
    Schachter, M
    Shucard, DW
    Weider, V
    Catalano, BA
    Cervi, JM
    Czekay, C
    Farrell, JL
    Filippini, JS
    Matyas, RC
    Michienzi, KE
    Ito, M
    OMalley, JA
    [J]. ANNALS OF NEUROLOGY, 1996, 39 (03) : 285 - 294
  • [10] Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis
    Kappos, L
    Polman, C
    Pozzilli, C
    Thompson, A
    Dahlke, F
    Knight, R
    Hern, J
    Coleman, R
    Gerrie, L
    Cooper, G
    Moore, J
    Boringa, J
    van Oosten, B
    Ronner, H
    Schrijver, H
    Truyen, L
    Montalbán, J
    Río, J
    Tintoré, M
    Jacas, C
    Marzo, E
    Lechner-Scott, J
    Huber, S
    Lienert, C
    Brunnschweiler, H
    Hawkins, S
    Droogan, A
    McDonnell, G
    Duddy, M
    McKinstry, S
    Altenkirch, H
    Baum, K
    Einhäupl, K
    Marx, P
    Poewe, W
    Walter, G
    Akman, H
    Brockmeier, B
    Scherer, P
    Zschenderlein, R
    Schmierer, K
    Gelderblom, H
    Hartmann, A
    Stapf, C
    Lüschow, A
    Mackert, B
    Schumacher, H
    Masuhr, F
    Hempel, T
    Zimmermann, R
    [J]. LANCET, 1998, 352 (9139) : 1491 - 1497